Clopidogrel
Product Images NDC 53002-1672

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 53002-1672). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal bar chart titled 'Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel Bisulfate 75 mg Alone or with Proton Pump Inhibitors (PPIs)'. The chart shows the effect on active metabolite AUC with mean and 90% confidence intervals for four PPIs: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, plotted against a horizontal axis labeled 'Change relative to clopidogrel bisulfate administered alone' ranging from 0.4 to 1.4.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph depicting cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up comparing placebo plus aspirin to Clopidogrel Bisulfate plus aspirin. The Clopidogrel group shows consistently lower event rates than the placebo group. A p-value of 0.00009 is indicated, and a note mentions other standard therapies were used as appropriate.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

A forest plot chart presenting subgroup analyses comparing Clopidogrel Bisulfate and placebo. It shows hazard ratios with 95% confidence intervals across various subgroups including age, gender, race, elevated cardiac enzymes, diabetes status, history of myocardial infarction and stroke, and concurrent use of medications like Heparin/LMWH, Aspirin, GPIIb/IIIa antagonists, Beta-Blockers, and ACE inhibitors. The chart visually indicates which subgroups favor Clopidogrel Bisulfate or placebo based on the hazard ratios.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A Kaplan-Meier survival curve chart showing the percentage of death before first discharge over days since randomization up to 28 days. It compares two groups: Placebo with 1845 deaths (8.1%) and Clopidogrel with 1726 deaths (7.5%), indicating a 7% proportional risk reduction (p = 0.03).*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A Kaplan-Meier curve comparing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days between Clopidogrel and placebo groups. The graph shows a lower event rate for Clopidogrel (9.2%) compared to placebo (10.1%) with a 9% proportional risk reduction (p = 0.002). The x-axis represents days since randomization, and the y-axis shows the percentage of events.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot showing odds ratios with 99% confidence intervals for various subgroups comparing Clopidogrel Bisulfate versus placebo. Subgroups include gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, with data on number of subjects and event percentages.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph comparing the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up between aspirin and clopidogrel bisulfate. The graph shows event rates increasing over time for both, with aspirin having a slightly higher rate. A p-value of 0.045 is noted, indicating statistical comparison.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A forest plot chart comparing Clopidogrel Bisulfate and Aspirin across qualifying conditions including Stroke, MI, and PAD, showing the number and percentage of events for each treatment group and hazard ratios with 95% confidence intervals, illustrating the relative favorability between Clopidogrel Bisulfate and Aspirin treatments.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure diagram of Clopidogrel bisulfate showing atomic connections and ring structures with sulfur and chlorine atoms clearly marked.*

FDA Label Image

Label Image (Lbl530021672)

Clopidogrel 75 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label indicates a count of 30 tablets with instructions to take one tablet daily as directed. It includes dosage strength, product NDC 53002-1672, and sections for patient name, prescribing doctor, and pharmacy information. The label also lists lot number, expiration date, and billing NDC codes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.